These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

455 related items for PubMed ID: 18350737

  • 21. Orlistat increases serum paraoxonase activity in obese patients.
    Audikovszky M, Pados G, Seres I, Harangi M, Fülöp P, Katona E, Illyés L, Winkler G, Katona EM, Paragh G.
    Nutr Metab Cardiovasc Dis; 2007 May; 17(4):268-73. PubMed ID: 17134960
    [Abstract] [Full Text] [Related]

  • 22. Who will lose weight on sibutramine and orlistat? Psychological correlates for treatment success.
    Elfhag K, Finer N, Rössner S.
    Diabetes Obes Metab; 2008 Jun; 10(6):498-505. PubMed ID: 17593239
    [Abstract] [Full Text] [Related]

  • 23. Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial.
    Wadden TA, Berkowitz RI, Womble LG, Sarwer DB, Arnold ME, Steinberg CM.
    Obes Res; 2000 Sep; 8(6):431-7. PubMed ID: 11011909
    [Abstract] [Full Text] [Related]

  • 24. Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study.
    Richelsen B, Tonstad S, Rössner S, Toubro S, Niskanen L, Madsbad S, Mustajoki P, Rissanen A.
    Diabetes Care; 2007 Jan; 30(1):27-32. PubMed ID: 17192328
    [Abstract] [Full Text] [Related]

  • 25. Blood pressure changes associated with sibutramine and weight management - an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT).
    Sharma AM, Caterson ID, Coutinho W, Finer N, Van Gaal L, Maggioni AP, Torp-Pedersen C, Bacher HP, Shepherd GM, James WP, SCOUT Investigators.
    Diabetes Obes Metab; 2009 Mar; 11(3):239-50. PubMed ID: 18671798
    [Abstract] [Full Text] [Related]

  • 26. [The effect of sibutramine for the maintenance of weight loss. A randomized controlled clinical trial].
    Toubro S, Hansen DL, Hilsted JC, Porsborg PA, Astrup AV, STORM Study Group.
    Ugeskr Laeger; 2001 May 21; 163(21):2935-40. PubMed ID: 11402974
    [Abstract] [Full Text] [Related]

  • 27. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity.
    Gokcel A, Gumurdulu Y, Karakose H, Melek Ertorer E, Tanaci N, BascilTutuncu N, Guvener N.
    Diabetes Obes Metab; 2002 Jan 21; 4(1):49-55. PubMed ID: 11874442
    [Abstract] [Full Text] [Related]

  • 28. The effect of 1-yr sibutramine treatment on glucose tolerance, insulin sensitivity and serum lipid profiles in obese subjects.
    Sabuncu T, Ucar E, Birden F, Yasar O.
    Diabetes Nutr Metab; 2004 Apr 21; 17(2):103-7. PubMed ID: 15244102
    [Abstract] [Full Text] [Related]

  • 29. Orlistat as an adjunct therapy in type 2 obese diabetic patients treated with sulphonylurea: a Bangladesh experience.
    Pathan MF, Latif ZA, Nazneen NE, Mili SU.
    Bangladesh Med Res Counc Bull; 2004 Apr 21; 30(1):1-8. PubMed ID: 15376463
    [Abstract] [Full Text] [Related]

  • 30. A randomized double-blind study comparing the efficacy and safety of orlistat versus placebo in obese patients with mild to moderate hypercholesterolemia.
    de Castro JJ, Dias T, Chambel P, Carvalheiro M, Correia LG, Guerreiro L, Marques O, Medina JL, Nobre E, Nunes JS, Pereiraa MC, Polónia J, Portugal J, Raimundo A, Ruas A, da Silva PM, Vasconcelos C, Reis JL, Teles AG.
    Rev Port Cardiol; 2009 Dec 21; 28(12):1361-74. PubMed ID: 20301983
    [Abstract] [Full Text] [Related]

  • 31. Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study.
    Florakis D, Diamanti-Kandarakis E, Katsikis I, Nassis GP, Karkanaki A, Georgopoulos N, Panidis D.
    Int J Obes (Lond); 2008 Apr 21; 32(4):692-9. PubMed ID: 18071341
    [Abstract] [Full Text] [Related]

  • 32. Efficacy of weight loss drugs on obesity and cardiovascular risk factors in obese adolescents: a meta-analysis of randomized controlled trials.
    Czernichow S, Lee CM, Barzi F, Greenfield JR, Baur LA, Chalmers J, Woodward M, Huxley RR.
    Obes Rev; 2010 Feb 21; 11(2):150-8. PubMed ID: 19573052
    [Abstract] [Full Text] [Related]

  • 33. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group.
    Rössner S, Sjöström L, Noack R, Meinders AE, Noseda G.
    Obes Res; 2000 Jan 21; 8(1):49-61. PubMed ID: 10678259
    [Abstract] [Full Text] [Related]

  • 34. Cholesterol lowering effect of dietary weight loss and orlistat treatment--efficacy and limitations.
    Erdmann J, Lippl F, Klose G, Schusdziarra V.
    Aliment Pharmacol Ther; 2004 Jun 01; 19(11):1173-9. PubMed ID: 15153170
    [Abstract] [Full Text] [Related]

  • 35. Efficacy and safety of sibutramine in 2225 subjects with cardiovascular risk factors: short-term, open-label, observational study.
    Gaciong Z, Placha G.
    J Hum Hypertens; 2005 Sep 01; 19(9):737-43. PubMed ID: 15905888
    [Abstract] [Full Text] [Related]

  • 36. Six-month treatment of obesity with sibutramine 15 mg; a double-blind, placebo-controlled monocenter clinical trial in a Hispanic population.
    Cuellar GE, Ruiz AM, Monsalve MC, Berber A.
    Obes Res; 2000 Jan 01; 8(1):71-82. PubMed ID: 10678261
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Effects of orlistat on obesity-related diseases - a six-month randomized trial.
    Guy-Grand B, Drouin P, Eschwège E, Gin H, Joubert JM, Valensi P.
    Diabetes Obes Metab; 2004 Sep 01; 6(5):375-83. PubMed ID: 15287931
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.